1Elevan Bio

Executive Summary

1Elevan Bio is a private biopharmaceutical company redefining peptide therapeutics through precision medicine and advanced delivery systems. Founded in 2021 and headquartered in Cambridge, MA, the company specializes in FDA-approved and FDA-expanded-access peptides that offer enhanced efficacy, superior safety profiles, and fewer side effects compared to traditional pharmaceuticals. Their focus on precision peptides targets transformative treatments in immunology and cell therapy, leveraging cutting-edge research to address unmet medical needs. With a stage classified as "Approved," 1Elevan has successfully navigated regulatory pathways, indicating at least one commercialized product and a pipeline of expanded-access programs. Looking ahead, 1Elevan Bio is poised to expand its therapeutic reach through ongoing clinical development and potential new indications. The company's emphasis on precision and safety positions it well in the competitive peptide therapeutics market, though limited public information on financials and pipeline depth constrains visibility. Strategic partnerships or further FDA approvals could accelerate growth, making 1Elevan a notable but early-stage player in the evolving landscape of targeted protein-based therapies.

Upcoming Catalysts (preview)

• Q2 2027FDA approval of a new peptide therapy for an autoimmune indication55% success
• TBDExpansion of expanded access program to additional disease areas70% success
• Q4 2026Announcement of a strategic partnership for commercial distribution60% success